This product consists of a polyclonal population of GPC1 knockout HEK293T cells generated by CRISPR/Cas9-mediated disruption of the human GPC1 gene. The heterogeneous knockout pool avoids clonal artifacts and enables loss-of-function studies of glypican-1, a cell-surface heparan sulfate proteoglycan co-receptor for growth factor families including FGF, VEGF, Wnt, and Hedgehog. Researchers use these cells to investigate signal transduction, exosome biology, and oncogenic mechanisms in a tractable system.
The HEK293T host line is a derivative of HEK293 that stably expresses SV40 large T antigen, enabling high-level episomal replication and efficient protein expression. Originating from human embryonic kidney, these cells are widely used for viral packaging, gene editing, and recombinant protein production. Their rapid growth and epithelial morphology make them an ideal platform for examining proteoglycan-mediated signaling, and in the GPC1 knockout context, they provide a relevant background for studying growth factor interactions without lineage-specific confounders.
Glypican-1 is a GPI-anchored heparan sulfate proteoglycan that functions as a co-receptor for Wnt, FGF, Hedgehog, and VEGF ligands. It binds FGF2, VEGF165, Wnt3a, and Hedgehog morphogens, presenting them to receptors such as FGFR1, VEGFR2, Frizzled/LRP5/6, and Patched/Smoothened. Downstream signaling involves ??-catenin/TCF/LEF, ERK, GLI, and AKT cascades. GPC1 also interacts with integrins to modulate adhesion and migration. Knockout disrupts ligand?Creceptor complex formation, attenuating signal transduction and altering cell proliferation and motility.
In HEK293T cells, GPC1 knockout enables dissection of heparan sulfate-dependent signaling, as these cells express endogenous Wnt and FGF pathway components. The model reveals compensatory mechanisms and context-specific roles of GPC1 in cross-talk among mitogenic signals. Given HEK293T’s common use for exosome production, this knockout is valuable for investigating GPC1’s role in exosomal cargo sorting and biomarker potential, as GPC1-positive exosomes are linked to cancer detection. The SV40 large T antigen ensures genomic stability for long-term studies.
These polyclonal GPC1 knockout HEK293T cells support cancer biology, signal transduction, and drug target validation studies. Assays include proliferation (BrdU), migration (scratch-wound), tube formation, and phospho-protein analysis by Western blot or flow cytometry for ??-catenin, ERK, AKT, and GLI. Co-immunoprecipitation and immunofluorescence examine ligand?Creceptor interactions, while RNA-seq reveals transcriptomic changes. The heterogeneous pool is ideal for high-throughput screens to identify synthetic lethal partners or modulators targeting GPC1-deficient cancer cells. Please contact Ascent Research for protocols or specifications.
